Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 3/20 | 0.38 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.36 |
| ▸ | MMP2 | P08253 | 2/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.35 |
| ▸ | BHMT | Q93088 | 1/20 | 0.34 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3997932 | 1.00 | ANPEP (0.38) | ANPEPENPEPDPP4ALDH1A1LTA4H | |
| SCHEMBL3998080 | 1.00 | ANPEP (0.38) | ANPEPENPEPDPP4ALDH1A1LTA4H | |
| SCHEMBL3994738 | 0.98 | ALDH1A1 (0.39) | ANPEPENPEPDPP4ALDH1A1LTA4H | |
| SCHEMBL3996141 | 0.98 | ALDH1A1 (0.39) | ANPEPENPEPDPP4ALDH1A1LTA4H | |
| SCHEMBL3996436 | 0.98 | ALDH1A1 (0.39) | ANPEPENPEPDPP4ALDH1A1LTA4H | |
| SCHEMBL3994568 | 0.97 | ANPEP (0.38) | ANPEPENPEPDPP4ALDH1A1LTA4H | |
| SCHEMBL3994863 | 0.97 | ANPEP (0.38) | ANPEPENPEPDPP4ALDH1A1LTA4H | |
| SCHEMBL3997853 | 0.97 | ANPEP (0.38) | ANPEPENPEPDPP4ALDH1A1LTA4H | |
| SCHEMBL3997954 | 0.93 | ANPEP (0.44) | ANPEPENPEPALDH1A1LTA4HBHMT | |
| SCHEMBL4000456 | 0.93 | ANPEP (0.44) | ANPEPENPEPALDH1A1LTA4HBHMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517909-B2 | Amino acids with affinity for the α2δ-protein | PFIZER INC (US) | 2009-04-14 | — | — | US | disclosed |
| US-20060247282-A1 | Methods for using amino acids with affinity for the alpha2delta-protein | BRAMSON CANDACE | 2006-11-02 | — | — | US | disclosed |
| US-7112610-B2 | Methods for using amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2006-09-26 | — | — | US | disclosed |
| US-20060154972-A1 | Amino acids with affinity for the alpha-2-delta-protein | BARTA NANCY S | 2006-07-13 | — | — | US | disclosed |
| US-7064147-B2 | Amino acids with affinity for the α-2-delta-protein | WARNER-LAMBERT COMPANY (US) | 2006-06-20 | — | — | US | disclosed |
| US-20050124669-A1 | Methods for using amino acids with affinity for the alpha2delta-protein | BRAMSON CANDACE (US) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124669-A1 | Methods for using amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | ANPEP 477/4885ENPEP 1779/4885DPP4 2855/4885 |
| US-20060154972-A1 | Amino acids with affinity for the alpha-2-delta-protein | SCN2A, OPRD1, SCN1A | ANPEP 586/4885ENPEP 1440/4885DPP4 2698/4885 |
| US-20060247282-A1 | Methods for using amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | ANPEP 477/4885ENPEP 1779/4885DPP4 2855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.